期刊文献+

哌拉西林/他唑巴坦治疗术后腹腔感染140例临床疗效观察 被引量:5

Efficacy of Piperacillin/tazobactam on Postoperative Abdominal Infection : A Clinical Investigation
下载PDF
导出
摘要 目的评价哌拉西林/他唑巴坦(特治星)治疗外科手术后腹腔感染的有效性及安全性。方法对术后140例腹腔感染患者经验性采用哌拉西林/他唑巴坦抗感染治疗。结果治疗总有效率为90.6%,细菌清除率89.8%,不良反应率3.6%。结论哌拉西林/他唑巴坦治疗术后腹腔感染效果良好,具有高效、安全、低毒特点。 OBJECTIVE To evaluate the efficacy and safety of piperacillin/tazobactam in the treatment of postoperative abdominal infection. METHODS Totally 140 patients with postoperative abdominal infection were empirically treated by piperacillin/tazobactam as anti-totally inflammatory therapy. RESULTS The total effective rate was 90.6%, the bacteria eradication rate was 89. 9%, the rate of adverse reactions occurring was 3. 6%.CONCLUSIONS Piperacillin/tazobactam is a highly effective, safe and low toxic agent in the treatment of postoperative abdominal infection.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2005年第8期937-938,共2页 Chinese Journal of Nosocomiology
关键词 哌拉西林/他唑巴坦 术后腹腔感染 Piperacillin/tazobactam, Postoperative abdominal infection
  • 相关文献

参考文献6

二级参考文献20

  • 1薛国文,冷泰俊,邹英,时凤丽,周吉军.医院感染7年回顾与前瞻性监测[J].中华医院感染学杂志,1996,6(1):18-21. 被引量:79
  • 2-.医院获得性支气管-肺感染诊断标准[J].中华结核和呼吸杂志,1990,13:372-372.
  • 3戴自英.实用内科学:第11版[M].北京:人民卫生出版社,2001.1855-1859.
  • 4[1]Jones RN. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins[J]. Am J Health Syst Pharm, 1995, 15, 52(6 Suppl 2): S29-S33.
  • 5[2]Daley D, Mulgrave L, Munro R, et al. An evaluation of the in vitro activity of piperacillin/tazobactam[J]. Pathology, 1996, 28(2): 167-172.
  • 6Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group[J]. Arch Intern Med, 1999, 159: 2553-2560.
  • 7Singh N, Yu VL. Rational empiric antibiotic prescription in the ICU[J]. Chest, 2000, 117: 1496-1499.
  • 8Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics[J]. Arch Intern Med, 1991, 151(3): 886-895.
  • 9Gutmann L, Kitzis MD, Yamabe S, et al. Comparative evaluation of a new β-laetamase inhibitor, YTR830, combined with different β-laetam antibiotics against bacteria harboring known β-laetamses[J]. Antimierob Agents Chemother, 1986, 29(5): 955-962.
  • 10Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate[J]. Antimicrob Agents Chemother, 1989, 33(8): 1268-1274.

共引文献34

同被引文献72

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部